Cognition Therapeutics Stock Fundamentals
| CGTX Stock | USD 0.40 0.01 2.44% |
Cognition Therapeutics fundamentals help investors to digest information that contributes to Cognition Therapeutics' financial success or failures. It also enables traders to predict the movement of Cognition Stock. The fundamental analysis module provides a way to measure Cognition Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cognition Therapeutics stock.
At this time, Cognition Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Total Operating Expenses is likely to rise to about 53.3 M in 2024, whereas Net Interest Income is likely to drop (33.8 K) in 2024. Cognition | Select Account or Indicator |
Cognition Therapeutics Company Shares Outstanding Analysis
Cognition Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cognition Therapeutics Shares Outstanding | 41.55 M |
Most of Cognition Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cognition Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cognition Shares Outstanding Historical Pattern
Today, most investors in Cognition Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cognition Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cognition Therapeutics shares outstanding as a starting point in their analysis.
Cognition Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cognition Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Cognition Therapeutics has 41.55 M of shares currently outstending. This is 76.99% lower than that of the Biotechnology sector and 61.12% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 92.73% higher than that of the company.
Cognition Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cognition Therapeutics's current stock value. Our valuation model uses many indicators to compare Cognition Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cognition Therapeutics competition to find correlations between indicators driving Cognition Therapeutics's intrinsic value. More Info.Cognition Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cognition Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cognition Therapeutics' earnings, one of the primary drivers of an investment's value.Cognition Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cognition Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cognition Therapeutics could also be used in its relative valuation, which is a method of valuing Cognition Therapeutics by comparing valuation metrics of similar companies.Cognition Therapeutics is currently under evaluation in shares outstanding category among its peers.
Cognition Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.94 | ||||
| Current Valuation | (4.9 M) | ||||
| Shares Outstanding | 41.55 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 24.53 % | ||||
| Number Of Shares Shorted | 722.95 K | ||||
| Price To Book | 1.14 X | ||||
| EBITDA | (25.51 M) | ||||
| Net Income | (25.79 M) | ||||
| Cash And Equivalents | 46.61 M | ||||
| Cash Per Share | 1.94 X | ||||
| Total Debt | 1.24 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 0.76 X | ||||
| Cash Flow From Operations | (16.02 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 6.2 | ||||
| Number Of Employees | 25 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 16.53 M | ||||
| Total Asset | 35.16 M | ||||
| Retained Earnings | (141.19 M) | ||||
| Working Capital | 24.05 M | ||||
| Net Asset | 35.16 M |
About Cognition Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cognition Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognition Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognition Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.7 M | 1.5 M | |
| Cost Of Revenue | 252 K | 167 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.